ASCO GU 2022: First-Line Avelumab May Benefit Cisplatin Ineligible Advanced Urothelial Cancer Patients
No difference in outcomes was observed based on degree of PD-L1 expression
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.